공시 • Jun 20
KKR Reportedly Eyes at Least $1 Billion Stake in Medicover's India Hospital Arm KKR & Co. Inc. (NYSE:KKR) is in advanced talks to buy a majority stake in the Indian business of Sweden’s Medicover AB (publ) (OM:MCOV B) for at least $1 billion, a source with direct knowledge of the matter said, a deal that would expand its healthcare bet in the world’s most populous nation. Stockholm-listed Medicover issued a press release soon after Reuters sent a request for comment on Wednesday night, saying Medicover Hospitals India (Medicover Healthcare Private Limited) is in discussions with KKR “regarding a potential sale of its Indian operations.”The company did not provide any details and Reuters is first to report that talks are ongoing for KKR to take a majority stake in the Indian business unit for at least $1 billion. Medicover, which entered the country in 2016, operates a network of 26 hospitals with around 6,000 beds. In its statement, it said it has also been preparing for an Indian initial public offering. Sweden’s Medicover owns 66.9 per cent of Medicover Hospitals India. KKR is seeking to acquire the Swedish firm’s entire stake for at least $1.05 billion and is also in discussions with minority shareholders. The “discussions are ongoing and a non-binding agreement has been reached,” said the person, who declined to be named publicly as the talks are private. Medicover did not respond to Reuters queries and KKR declined to comment. In its press release, Medicover said there is no certainty that discussions with KKR will result in any transaction and that the firm is continuing with the IPO process. KKR has been steadily increasing its healthcare investments in India. In 2024, the buyout firm bought a controlling stake in a hospital chain in the southern state of Kerala and has since backed the hospital group’s expansion through acquisitions. India’s hospital sector has attracted strong investor interest as rising incomes, expanding health insurance coverage and growing demand for quality healthcare drive consolidation and capacity expansion across the industry. Medicover competes with Apollo Hospitals, Aster Hospitals, and Fortis Healthcare in India. Rothschild is advising on the sale process, while Kotak is advising KKR, the person added. Kotak and Rothschild did not respond to Reuters queries. 공시 • Oct 23
Medicover Announces Additional Results from the Ongoing Dart Clinical Study from Oslo University Hospital Medicover announced additional results from the ongoing DART clinical study from Oslo University Hospital. The study utilises Medicover Genetics' hybrid capture-based, tumour-agnostic MRD assay. The additional results are based on an expanded population within the DART study and further strengthen the value of Medicover Genetics' ctDNA-based minimal residual disease (MRD) assay as a predictor of disease progression in patients with unresectable stage III non-small cell lung cancer (NSCLC). The results were presented through a poster presentation on 18 October 2025, at the European Society for Medical Oncology (ESMO) Congress in Berlin, where the study was recognised with one of the congress' Best Poster awards. The additional results represent another key milestone towards the clinical validation of Medicover Genetics' MRD assay and commercialisation. The mature data include 640 plasma samples from 84 patients. The study demonstrates that detectable circulating tumour DNA (ctDNA) during and after consolidative durvalumab following chemoradiotherapy (CRT) is strongly associated with inferior progression-free survival (PFS) and can predict disease progression months before radiological evidence. Data from the full 86-patient cohort will follow during the first half of 2026. Detection of ctDNA at six months after the initiation of durvalumab treatment was associated with inferior PFS (HR=2.45; 95% CI: 1.18-5.11; p=0.017). Likewise, detection of ctDNA three months after the end of durvalumab treatment were also associated with inferior PFS (HR=5.37; 95% CI: 1.,93-14.93; p=0.001). Importantly, ctDNA detection preceded imaging-based progression by a median of 7.4 months, demonstrating its potential as an early indicator of disease progression. The DART study (NCT04392505 /EudraCT 2019-002537-11) is a multicentre, prospective phase II trial including 86 patients with unresectable stage II NSCLC across several European centres. The study utilises Medic over Genetics' hybrid capture-based., tumour-agnostic MR DART assay, designed to detect and monitor minimal residual disease. 공시 • Oct 03
Medicover AB (publ), Annual General Meeting, Apr 29, 2026 Medicover AB (publ), Annual General Meeting, Apr 29, 2026. 공시 • Jun 19
Medicover AB (Publ) Announces Executive Changes Medicover AB (publ) announced Lukasz Krause will assume the role of CDIO as of 1 July 2025 and be part of the executive management team of Medicover. Lukasz brings a wealth of experience in IT management having successfully overseen the IT function for two-thirds of Medicover organisation as Head of IT for the Healthcare Services division over the past three years. He also brings extensive experience in managing IT in reputable international corporations prior to joining Medicover. Lukasz succeeds Jarek Urbanczyk, who is leaving the company after nearly 6 years of service. 공시 • Jun 03
Medicover Announces Positive Interim Results from the DART Clinical Study Medicover announced positive interim results from the DART clinical study conducted by Oslo University Hospital. The interim results indicate that by using Medicover Genetics' minimal residual disease (MRD) assay, MRD can be detected in patients with stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy and durvalumab consolidation. In addition, it was found that detection of MRD during consolidative durvalumab was associated with inferior outcomes. The interim results were presented by Professor Aslaug Helland of Oslo University Hospital at the 2025 ASCO Annual Meeting. The interim results present a key milestone towards clinical validation of Medicover Genetics' MRD assay and commercialization. The DART study is a multicenter phase II clinical trial including 85 patients with unresectable stage III non-small cell Lung cancer (NSCLC) across multiple sites in Europe. All participants received chemoradiotherapy (CRT) followed by durvalumab consolidation therapy. Longitudinal plasma samples were collected at baseline (pre-CRT), at the initiation of durvalumab, and at predefined timepoints during durvalumab treatment and surveillance. The samples were analyzed using Medicover Genetics' novel, tumor-agnostic ctDNA-based MRD assay, which evaluates 293 genes and is tailored to each patient's individual biomarker profile using hybrid capture-based sequencing. The interim analysis included 20 patients who completed all scheduled blood draws, totaling 138 plasma samples. Key findings include: Detectable ctDNA in at least one plasma sample during the first four months after chemoradiotherapy was significantly associated with shorter progression-free survival (PFS) (HR: 4.7; 95% CI: 1.6-13.1; p = 0.004). Presence of ctDNA at four months post-CRT was also linked to shorter progression-free survival (HR: 3.77; 95% CI: 1.,32-10.74; p = 0.013). In contrast, ctDNA detection one month post-CRT was not significantly associated with reduced PFS (HR: 2.23; 95% CI: 0.78-6.36; p = 0.13). detection of ctDNA during the first four months post-CRT were associated with significantly increased odds of death within 24 months (OR: 16.48; 95% CI: 1; 1.29-1000.51; p = 0.017). These findings underscore the potential of ctDNA-basedMRD assessment as a prognostic biomarker to identify high-risk patients and guide more tailored interventions in this population. Ongoing Medicover work regarding the DART study is now focusing on completing the MRD testing for the entire patient cohort. 
